Psilocybin Therapy Works… But Not Like You Think, with Compass Pathways

If one or two psychedelic sessions can produce measurable improvements in treatment-resistant depression, why does modern psychiatry still rely on daily medication? In this episode of Divergent States , we sit down with Dr. Steve Levine, psychiatrist and Chief Patient Officer at Compass Pathways, to break down their newly released Phase 3 clinical trial results for COMP360 psilocybin therapy. But this isn’t a hype piece. This is a critical look at what the data actually shows—and what people might be getting wrong. We explore: – What Phase 3 trials really mean (and why they often fail) – Why a “3.8 point improvement” is more significant than it sounds – The difference between clinical psilocybin therapy and underground use – Why one or two sessions may work—but not for everyone – The role of neuroplasticity, subjective experience, and “set & setting” – Why scaling psychedelic therapy is harder than it looks – The tension between commercialization and psychedelic culture – What FDA approval would—and wouldn’t—change Compass Pathways has now run over 1,000 participants across Phase 2 and Phase 3 trials, showing statistically significant results in treatment-resistant depression. But translating that into real-world treatment is a completely different challenge. This conversation pulls back the curtain on what it actually takes to turn psychedelics into medicine—and where the limitations still are. Because this show isn’t about psychedelics being amazing. It’s about understanding what’s true… and what holds up under scrutiny. 🎧 Subscribe to Divergent States for grounded, skeptical conversations in psychedelic science, culture, and harm reduction. 💬 Join the community Discord via r/Psychonaut (link in subreddit) 🎶 Music: Elemental by [Drip] ⚠️ This podcast is for informational purposes only and does not constitute medical advice. Chapters: 00:00 If Psychedelics Work, Why Daily Medication? 01:15 Why This Isn’t a “Psychedelics Are Amazing” Episode 04:00 From Daily Pills to 1–2 Treatments 06:45 Why Ketamine Wasn’t the Breakthrough 09:25 What Phase 3 Trials Actually Prove (And Don’t) 12:50 What Regulators Are Really Looking For 14:25 What a “3.8 Score Improvement” Actually Means 15:55 Psychedelic Hype vs Reality 18:30 What Actually Stood Out in the Data 21:40 Why Psychedelics Work Faster 24:55 Is the Experience Part of the Treatment? 25:45 Why Set and Setting Still Matter 30:10 Will This Ever Be At-Home? 33:00 Why Therapists Don’t “Do Therapy” Here 34:40 The Real Problem: Scaling Access 39:00 Commercialization vs Psychedelic Culture 43:00 What Are the Actual Risks? 45:10 What Success Looks Like in 10 Years 47:10 Why Access Matters More Than Approval 49:50 Why This Fails in the Real World 52:10 Outro + Patreon Integration Session Send us Fan Mail Love the podcast? Help keep the conversations going by checking out our official merch shop! We've got t-shirts, hoodies, hats, mugs, stickers, and more, with new designs added regularly. Every purchase helps support independent, honest conversations about psychedelics, science, and culture. Shop now: https://divergent-states-shop.fourthwall.com/ FiresideProject.org Download the app or text/call 62-FIRESIDE Zendo Project Our listeners get 10% off the Zendo Project SIT Program with the code DIVERGENTS10 Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission